Anthem Biosciences Share Price Target 2025, 2026, 2030, 2040, 2050

Anthem Biosciences is a research and development company that helps other companies make medicines. They support the whole process, from finding new medicines, testing them, and finally making them in large amounts. They work with both chemical-based and biology-based medicines. They also make special products like GLP-1, enzymes, probiotics, and biosimilars using advanced science and technology. Their factories in Karnataka are well-equipped, safe, and follow high-quality standards. They work mostly with small and growing medicine companies.

What is the Anthem Biosciences Ltd NSE: ANTHEM?

Anthem Biosciences is a pharmaceutical company established in 2006 in Bengaluru by Dr. Ajay Bhardwaj. It helps other companies in making medicines, and it offers services like research, testing, and large-scale manufacturing. It has several modern factories in Karnataka that follow strict international quality rules. The company works with over 280 clients across the world, and more than 80% of its business comes from countries like the US, Europe, and China. It uses advanced methods to make medicines and health products like probiotics and vitamins.

Anthem Biosciences share price

Anthem Biosciences share price Target 2025

It provides services from early research to making the final product. It works with both small and large types of drug molecules, which helps the company give faster and more affordable services to its clients. The company uses advanced methods in RNA interference, antibody-drug combinations, peptides, fats, and special genetic materials. It is also known for using modern and eco-friendly techniques, like biotransformation, flow chemistry, and green chemistry, to make drug production better and reduce waste. In 2025, its share price target would be ₹1224, as per our analysis.

By our prediction, its share price would be between ₹583 to ₹1224 in 2025.

In the July 2025 quarter, retail investors increased their shares a lot, from 0.00% to 20.20% of this stock. The stock price also went up by 3.7% in the last 7 days. Foreign investors raised their holdings from 0.00% to 1.50%, and mutual funds bought more shares, increasing by 2.21%. This shows that many types of investors are feeling more confident about the company.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	583	1224

Month	Minimum Price  (Rs)	Maximum Price (Rs)
July	700	805
August	642	867
September	620	1054
October	583	1090
November	875	1140
December	1058	1224

Anthem Biosciences share price Target 2026

It offers all the services needed, from discovering new drugs to making them in large amounts. This helps smaller companies deal with problems like following rules, getting money, and increasing production. In the year FY25, it had a 96.76% success rate. This helps the company offer good services at lower costs, make more profit, and build strong, long-term relationships with its customers. The company has long-term partnerships with 287 customers, including small biotech companies, medium-sized drug companies, and large international firms. In 2026, its share price target would be ₹1846, as per our prediction.

Its share price would be between ₹1141 to ₹1846 in 2026, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1141	1846

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1141	1278
February	1185	1325
March	1200	1381
April	1240	1410
May	1278	1432
June	1290	1465
July	1321	1487
August	1365	1521
September	1387	1578
October	1421	1625
November	1478	1690
December	1587	1846

Share price Target 2027

It makes a wide range of special ingredients, including items like GLP-1, products made through fermentation, probiotics, enzymes, and biosimilars. Using its strong knowledge in biology and chemistry, the company has successfully created and sold products like natural Vitamin K2 and probiotics. Its business and income have been growing steadily over the past few years. .  In 2027, its share price target would be ₹2430, as per our analysis.

By our prediction, its share price would be between ₹1790 to ₹2430 in 2027.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	1790	2430

Share price Target 2028

The company runs modern and advanced manufacturing facilities in India that have the largest fermentation capacity among similar companies in the country. These facilities are highly automated and use advanced systems like distributed control systems, which help reduce the need for people to do things by hand and make sure the products are of high quality. . In 2028, its share price target would be ₹3050, as per our prediction.

Its share price would be between ₹2341 to ₹3050 in 2028, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	2341	3050

Share price Target 2029

The company works with many different customers around the world, from small biotech companies to big pharmaceutical firms. The company has been involved in creating active pharmaceutical ingredients (APIs) for several commercial products. It handles many types of projects, from early research to late development and commercial production. The company has hundreds of customers in over 44 countries, including the U.S., Europe, and Japan. It also holds several patents in India and other countries, with more patents on the way for new technologies. . In 2029, its share price target would be ₹3645, as per our analysis.

By our prediction, its share price would be between ₹2980 to ₹3645 in 2029.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	2980	3645

Anthem Biosciences share price Target 2030

It helps with every step of the drug-making process, from early research to full production, for both small molecules and biologics. It is known as one of the fastest-growing CRDMO companies in India. The company focuses on new ideas and uses modern technology and methods to offer a wide range of advanced services. Its business model is specially made to support small pharmaceutical and biotech companies through each stage of their work. It has built strong and long-lasting relationships with many loyal customers from different parts of the world. In 2030, its share price target would be ₹4242, as per our prediction.

Its share price would be between ₹3580 to ₹4242 in 2030, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	3580	4242

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	3580	3711
February	3625	3735
March	3658	3778
April	3680	3800
May	3711	3825
June	3725	3841
July	3754	3890
August	3768	3925
September	3780	3956
October	3799	4056
November	3894	4152
December	3989	4242

Share price Target 2040

It provides many services and works with different kinds of customers, including new biotech companies and large pharmaceutical companies from all over the world. The company has grown its revenue more than other companies like it in India and around the world. It has worked hard to offer new technologies and flexible ways to make products. These efforts help the company meet the changing needs of its customers while also being efficient and caring for the environment. In 2040, its share price target would be ₹9390, as per our analysis.

By our prediction, its share price would be between ₹8734 to ₹9390 in 2040.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	8734	9390

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	8734	8878
February	8768	8940
March	8790	8980
April	8860	9035
May	8889	9058
June	8964	9100
July	8980	9135
August	9022	9165
September	9057	9178
October	9087	9200
November	9112	9235
December	9182	9390

Share Price Target 2050

Over the years, it has done many projects for hundreds of customers, working on different drug molecules. It makes important ingredients and advanced materials for several medicines that are already being sold, and has helped develop these medicines from the very beginning. A big part of its income comes from making top-selling medicines for large pharmaceutical companies, and these medicines are expected to keep growing in sales. In 2050, its share price target would be ₹15520, as per our prediction.

Its share price would be between ₹14640 to ₹15520 in 2050, as per our analysis.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	14640	15520

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	14640	14780
February	14678	14876
March	14690	14956
April	14725	15087
May	14768	15132
June	14854	15190
July	14921	15235
August	14988	15358
September	15154	15390
October	15184	15425
November	15264	15487
December	15325	15520

Should I buy Anthem Biosciences stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	400	1224
2026	1141	1846
2027	1790	2430
2028	2341	3050
2029	2980	3645
2030	3580	4242
2040	8734	9390
2050	14640	15520

It is a good company to invest in for the future. It helps other companies make medicines and is growing well by working with many customers around the world. The company makes good profits, uses new technology, and has modern factories. There are some risks, like depending on a few big customers and delays in payments, but overall, it looks like a strong company with good chances to grow.

Anthem Biosciences earnings results (Financials)

	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Sales +	626	633	1,103	1,231	1,056
Expenses +	454	451	695	666	627
Operating Profit	172	182	408	566	429
OPM %	27%	29%	37%	46%	41%
Other Income +	21	21	37	49	139
Interest	18	20	17	10	7
Depreciation	61	62	62	58	64
Profit before tax	114	121	366	547	498
Tax %	32%	23%	26%	26%	23%
Net Profit +	77	93	271	406	386
EPS in Rs
Dividend Payout %	0%	0%	0%	0%	0%

Is Anthem Biosciences stock good to buy? (bull case & bear case)

Bull Case:

• It is a top company for making and developing special chemicals and medicines for other companies (CRDMO)
• The company’s revenue grew by 30% and profit went up by 23% in FY25
• Works with over 550 clients across 44 countries, so it has a global reach
• Less than 20% of its raw materials come from China, which reduces supply risks
• Many foreign companies are looking for alternatives to China (“China+1”), and India is a top choice
• Anthem is building more capacity to grow even more by mid-FY26
• Its profit margin is about 37% of earnings before expenses

Bear Case:

• Depends heavily on one US distributor
• Around 27% of its raw materials still come from a single Chinese supplier
• Most of its income is project-based; if a few projects fail or get delayed, earnings could fall

Conclusion

It is a fast-growing company that helps other companies make medicines, from early research to large production. It uses modern science to work on both chemical and natural drugs, and also makes things like probiotics, enzymes, and similar health products. Its factories in India are up-to-date and follow high safety and quality standards. The company works with customers from many countries, including the US, Europe, and Asia. As more companies want to work with partners outside of China, it has a good chance to grow even more.

FAQs